The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
Open accessAbstract
Background Alopecia areata (AA) is an autoimmune form of hair loss with limited treatments. Objective To evaluate the efficacy and safety of the Janus kinase inhibitors ritlecitinib and brepocitinib in patients who have AA with ≥ 50% scalp hair loss. Methods Patients were randomized to once-daily ritlecitinib, brepocitinib, or placebo. The primary efficacy endpoint was a 24-week change from baseline in the Severity of Alopecia Tool (SALT) score. The key secondary efficacy endpoint was the proportion of patients achieving 30% improvement in SALT score (SALT 30 ). Results The ritlecitinib, brepocitinib, and placebo groups included 48, 47, and 47 patients, respectively. At week 24, least-squares mean difference from placebo in SALT score change from baseline was 31.1 (95% confidence interval [CI], 18.8-43.5) for ritlecitinib and 49.2 (95% CI, 36.6-61.7) for brepocitinib ( P < .0001 for both comparisons with placebo). SALT 30 was achieved by 50% (90% CI, 38%-62%) of patients receiving ritlecitinib, 64% (90% CI, 51%-75%) receiving brepocitinib, and 2% (90% CI, 0%-9%) receiving placebo. Two patients experienced a serious adverse event (rhabdomyolysis) in the brepocitinib group only. Limitations Only a single-dosage regimen of each study drug was included. Conclusion Treatment with ritlecitinib or brepocitinib for 24 weeks was efficacious and generally well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Telliez, J.-B., Dowty, M. E., Wang, L., Jussif, J., Lin, T., Li, L., Moy, E., Balbo, P., Li, W., Zhao, Y., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00677 · Cited by 204
Cited by
Deuterium in drug discovery: progress, opportunities and challenges
Di Martino, R. M. C., Maxwell, B. D., & Pirali, T. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00703-8 · Cited by 539
Two Phase 3 Trials of Baricitinib for Alopecia Areata
King, B., Ohyama, M., Kwon, O., Zlotogorski, A., Ko, J., Mesinkovska, N. A., Hordinsky, M., Dutronc, Y., Wu, W.-S., McCollam, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2110343 · Cited by 506
Self-citationJanus kinase-targeting therapies in rheumatology: A mechanisms-based approach
Tanaka, Y., Luo, Y., O’Shea, J. J., & Nakayamada, S. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00726-8 · Cited by 501
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
Huang, I.-H., Chung, W.-H., Wu, P.-C., & Chen, C.-B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1068260 · Cited by 329
King, B., Zhang, X., Harcha, W. G., Szepietowski, J. C., Shapiro, J., Lynde, C., Mesinkovska, N. A., Zwillich, S. H., Napatalung, L., Wajsbrot, D., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00222-2 · Cited by 298
Self-citation
Metadata
- Authors
- King, B., Guttman-Yassky, E., Peeva, E., Banerjee, A., Sinclair, R., Pavel, A. B., Zhu, L., Cox, L. A., Craiglow, B., Chen, L., Banfield, C., Page, K., Zhang, W., & Vincent, M. S.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 85
- Issue
- 2
- Pages
- 379-387
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W3139214381
- Cited by
- 199
- References
- 1
- FWCI
- 34.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. https://app.cochat.ai/papers/10.1016/j.jaad.2021.03.050
- The paper
- King, B., Guttman-Yassky, E., Peeva, E., Banerjee, A., Sinclair, R., Pavel, A. B., Zhu, L., Cox, L. A., Craiglow, B., Chen, L., Banfield, C., Page, K., Zhang, W., & Vincent, M. S. (2021). A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2021.03.050
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.